BENITIONSClinical Trial Intelligence

Specific Electrophenotypes in Atrial Fibrillation

不适用 提前终止 NCT05366530

适应症Atrial Fibrillation
分期不适用
申办方Imperial College London
状态提前终止
受试者人数1 人
干预(药物)Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging
开始日期2022年5月19日
完成日期2024年8月27日
结果公布日2026年3月12日

摘要

This study will investigate a common heart rhythm disturbance (arrhythmia), atrial fibrillation (AF), to improve understanding of how best to treat it in different patients. Direct current cardioversion (DCCV) is a procedure that can revert the heart to a normal rhythm, however almost all patients will only have a transient benefit, and their heart will return to the abnormal rhythm, AF. Ablation is an invasive procedure that creates scar tissue within the heart to reduce the arrhythmias, with a longer lasting effect than DCCV. It has been used with success in AF that occurs occasionally (paroxysmal) but is not as effective in AF that is more long-lasting, also known as persistent AF. Persistent AF is major cause of symptoms of breathlessness and palpitations and significantly increases the risk of stroke. Doctors are unable to accurately predict which patients will benefit most from an ablation, this can lead to as many as 50% of patients not benefitting from the procedure. The aim is to better predict which patients will benefit from an ablation. The study will include patients undergoing AF ablation or DCCV and perform additional tests including blood tests a heart MRI scan, a s

Freedom From Atrial Fibrillation

1 year

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。